160 completed, 65 recruiting, 50 terminated, 49 active not recruiting. 189 Phase 2, 102 Phase 1, 62 Phase 3, 11 Phase 4, 3 Early Phase 1.
Follow enzalutamide: new trials by email Literature Review of enzalutamide trials Research Report on enzalutamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 290 | 2026-12-14 | 2026-11-02 |
| Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT) Radiotherapy for MDT ± WPRT, Androgen Deprivation Therapy (ADT), Enzalutamide - Prostatic Neoplasms, Biochemical Recurrence | Phase 3 | Not yet recruiting | Ente Ospedaliero Cantonale, Bellinzona | 140 | 2026-11-01 | 2026-08-24 |
| A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer. ADT plus abiraterone or other ARPIs（apalutamide, enzalutamide, rezvilutamide, darolutamide) - Metastatic Hormone-Sensitive Prostate Cancer | Phase 2 | Not yet recruiting | Anhui Medical University | 40 | 2026-10-01 | 2026-08-31 |
| A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer fezolinetant, enzalutamide, apalutamide - Prostate Cancer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 56 | 2026-09-25 | 2026-10-16 |
| AXT-1003 Combination With Enzalutamide in Participants With mCRPC AXT-1003, Enzalutamide - mCRPC | Phase 1 | Recruiting | Axter Therapeutics (Beijing) Co., Ltd | 105 | 2026-09-24 | 2026-10-27 |
| Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) tinengotinib 10 mg QD plus darolutamide, tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide, tinengotinib 10 mg QD plus enzalutamide - Prostate Cancer (CRPC) | Phase 2 | Recruiting | TransThera Sciences (Nanjing), Inc. | 182 | 2026-09-18 | 2026-10-13 |
| Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) Saruparib, Placebo, Enzalutamide - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Recruiting | AstraZeneca | 1330 | 2026-09-15 | 2026-10-15 |
| A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302] Risvutatug rezetecan (Ris-Rez), Enzalutamide, Abiraterone - Neoplasms, Prostate | Phase 3 | Recruiting | GlaxoSmithKline | 684 | 2026-09-01 | 2026-10-02 |
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC | Phase 3 | Recruiting | University College, London | 1500 | 2026-08-28 | 2026-11-04 |
| A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC) darolutamide plus androgen deprivation therapy, Enzalutamide plus androgen deprivation therapy - Metastatic Castration Sensitive Prostate Cancer (mCSPC) | Active not recruiting | Pfizer | 4700 | 2026-08-19 | 2026-10-06 | |
| A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) Rinzimetostat, Darolutamide, Enzalutamide - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Recruiting | ORIC Pharmaceuticals | 600 | 2026-08-03 | 2026-11-03 |
| A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy Mevrometostat, Enzalutamide - Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma) | Phase 2 | Not yet recruiting | Prostate Cancer Clinical Trials Consortium | 60 | 2026-08-01 | 2026-05-18 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer CP-PCA07, Enzalutamide 40 mg capsule - Castration-Resistant Prostate Cancer (CRPC) | Phase 1 | Not yet recruiting | Hyundai Bioscience Co., Ltd. | 18 | 2026-07-01 | 2026-07-06 |
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-06-01 | 2026-05-05 |
| A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer INR731, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Novartis Pharmaceuticals | 208 | 2026-05-25 | 2026-10-23 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide Talazoparib with enzalutamide, Talazoparib - Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 2 | Recruiting | Prostate Cancer Clinical Trials Consortium | 126 | 2026-05-04 | 2026-08-21 |
Showing 20 of 358. Sign in to see all of them.
Prostatic Neoplasms (202) · Neoplasm Metastasis (23) · Prostatic Neoplasms, Castration-Resistant (20) · Breast Neoplasms (19) · Neoplasms (18) · Carcinoma, Non-Small-Cell Lung (6) · Triple Negative Breast Neoplasms (6) · Adenocarcinoma (5) · Bulbo-Spinal Atrophy, X-Linked (5) · Colorectal Neoplasms (5) · Pancreatic Neoplasms (5) · Parkinson Disease 4, Autosomal Dominant Lewy Body (5) · Carcinoma, Hepatocellular (4) · Melanoma (4) · Carcinoma, Renal Cell (3)
Pfizer (31) · Astellas Pharma Global Development, Inc. (13) · Astellas Pharma Europe B.V. (11) · Bayer (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (10) · Merck Sharp & Dohme LLC (9) · Astellas Pharma Inc (8) · AstraZeneca (8) · Memorial Sloan Kettering Cancer Center (8) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (6) · GlaxoSmithKline (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · Novartis Pharmaceuticals (5) · OHSU Knight Cancer Institute (5)
United States (244) · Spain (72) · United Kingdom (70) · Canada (60) · Australia (55) · France (55) · Italy (54) · China (45) · Germany (45) · South Korea (42) · Japan (36) · Belgium (35) · Netherlands (35) · Poland (31) · Taiwan (31)
Samuel Denmeade, MD (5) · Jingsong Zhang, MD, PhD (3) · Kim N Chi, MD (3) · Michael Schweizer (3)
PMID 22894553, PMID 25917876, PMID 35731340, PMID 25687533, PMID 35643841, PMID 20398925, PMID 24881730, PMID 25104109, PMID 25888263, PMID 25929560, PMID 25937426, PMID 30189902, PMID 31830211, PMID 32923850, PMID 34518652, PMID 35110415, PMID 35405009, PMID 38421243, PMID 39404227, PMID 40539499, PMID 41732008, PMID 41894648, PMID 42108644, PMID 11905923, PMID 18309951, PMID 18423743, PMID 18777528, PMID 18930581, PMID 18990168, PMID 19097774, PMID 19359544, PMID 19399748, PMID 19455472, PMID 19996060, PMID 20116997, PMID 21859989, PMID 22452894, PMID 22747660, PMID 23063623, PMID 23096187, PMID 23163774, PMID 23228172, PMID 23671006, PMID 23813930, PMID 23910941, PMID 23999218, PMID 24258798, PMID 24321502, PMID 24510426, PMID 24590644
2023 (14), 2016 (7), 2014 (5), 2019 (5), 2015 (4), 2017 (4), 2018 (4), 2025 (4), P30CA093373 (3), P30CA015704 (2), P50CA097186 (2), 2004 (1), 2009 (1), I01CX002277 (1), P01CA203628 (1)